Physician profile
David Hecker
NPI 1235248238
$19,267.78
in general payments reported to CMS, 2019-2025
31 companies · $4,085 in 2025
The $4,085 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $1,419 · 2021: $2,651 · 2022: $2,040 · 2023: $2,994 · 2024: $4,007 · 2025: $4,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,965.25 |
| Education | $120.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,983.86 | 2019-2025 | |
| Genzyme Corporation | $1,806.29 | 2019-2025 | |
| Janssen Biotech, INC. | $1,655.09 | 2019-2025 | Tremfya |
| Incyte Corporation | $1,588.32 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $1,509.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,411.68 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $1,039.01 | 2019-2025 | |
| Lilly USA, LLC | $978.77 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $846.20 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Sun Pharmaceutical Industries INC. | $836.56 | 2019-2025 | Ilumya, Winlevi |
| Ucb, INC. | $807.68 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $599.15 | 2022-2025 | Sotyktu |
| Amgen INC. | $538.85 | 2020-2025 | Otezla, Otezla |
| Allergan, INC. | $379.17 | 2019 | |
| Almirall LLC | $240.31 | 2021-2025 | Klisyri, Seysara |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $203.43 | 2023-2025 | Zoryve |
| Merz North America, INC. | $142.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.35 | 2022-2025 | Spevigo |
| Leo Pharma INC. | $123.75 | 2022-2025 | Adbry, Anzupgo |
| Vyne Pharmaceuticals INC. | $92.70 | 2020-2021 | |
| Dermavant Sciences, INC. | $61.99 | 2022-2023 | Vtama |
| Biofrontera INC. | $54.42 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.96 | 2019-2025 | Arazlo, Jublia, Duobrii |
| Verrica Pharmaceuticals INC. | $44.39 | 2023 | Ycanth |
| Celgene Corporation | $40.99 | 2019 | |
| Strata Skin Sciences, INC. | $25.83 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $21.40 | 2020 | |
| Mayne Pharma Commercial LLC | $15.30 | 2025 | |
| Fresenius Kabi USA, LLC | $15.25 | 2024 | Idacio |
| Nabriva Therapeutics, Plc | $11.73 | 2022 | |
| Dermira, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.